/C O R R E C T I O N -- AstraZeneca/
11 September 2004 - 11:10AM
PR Newswire (US)
/C O R R E C T I O N -- AstraZeneca/ In the news release, FDA
Advisory Committee Recommends Further Data to Support Approval of
AstraZeneca's Oral Anticoagulant Exanta(R), issued earlier this
evening by AstraZeneca over PR Newswire, we are advised by the
company that following the third paragraph of the release there
should be a fourth paragraph reading: "EXANTA is an investigational
oral direct thrombin inhibitor (oral DTI) and is poised to be the
first oral anticoagulant since the development of warfarin more
than 50 years ago. More than 30,000 patients in over 25 countries
have participated in the clinical trial program for EXANTA to date,
with more than 17,000 patients receiving EXANTA. EXANTA was studied
as a fixed, oral dose with no titration or coagulation monitoring,"
instead of being followed by the paragraph headed, "About
AstraZeneca," as originally issued inadvertently. PRNewswire --
Sept. 10 DATASOURCE: AstraZeneca
Copyright